A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). (Q35621565)

9 August 2017

1 reference

title

A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). (English)

1 reference

non-alcoholic steatohepatitis

9 August 2017

0 references

1 reference

J Fehér

1 reference

9 August 2017

G Lengyel

series ordinal

1 reference

9 August 2017

publication date

1 November 2003

1 reference

Journal of International Medical Research

9 August 2017

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

537-551

1 reference

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Oxidative stress-related molecules and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Liver disease in the pregnant patient. American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Treatment of nonalcoholic fatty liver: present and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Nonalcoholic steatohepatitis: a study of 49 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Persistent hyperaminotransferasemia resolving after weight reduction in obese children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000303100610

10.1177/147323000303100610

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference